Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial

Bristol Myers' (BMY) Sotyktu gets approval from the European Commission to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

Bristol Myers (BMY) Gets Approval of Psoriasis Drug in EU

Eli Lilly

Big pharma stocks ought to perform well in the current high interest rate environment. Eli Lilly and Bristol Myers Squibb have long been top value plays.

Is Eli Lilly or Bristol Myers Squibb the Better Value Stock to Buy Right Now?

Milvexian is a drug candidate under development by Bristol Myers and Johnson & Johnson. In a phase 2 clinical trial, milvexian produced encouraging results in preventing strokes.

Could This Drug Candidate Be a Winner for These 2 Big Pharma Stocks?

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

Evotec SE

8-YEAR EXTENSION AND EXPANSION OF ONGOING COLLABORATION TO DEVELOP A BROADENED PROGRAMME PIPELINE IN NEURODEGENERATIVE DISEASES PARTNERSHIP LEVERAGES EVOTEC'S PRECISION MEDICINE PLATFORMS FINANICAL TERMS INCLUDE $ 50 M UPFRONT PAYMENT, PERFORMANCE MILESTONES AND TIERED ROYALTIES ON PRODUCT SALES HAMBURG, GERMANY / ACCESSWIRE / March 28, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb (NYSE: BMY), originally signed in 2016. The initial partnership proved highly productive in generating a promising pipeline of discovery to clinical-stage programmes.

Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership

I expected Bristol-Myers Squibb Company stock to keep rising in value through 2023 and perhaps reach triple figures. Instead, the share price has fallen 5% this year as inflationary headwinds and drug pricing issues have weighed heavily on the sector.

Bristol-Myers Squibb: Nobody Panic! Share Price Stumble Shouldn't Last

Comcast

Cintas Corp

Home Depot

Intuit

Lowe's

Mastercard

Pfizer

Toronto-Dominion Bank

UnitedHealth Group

This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for consideration. To rank stocks, I sort them in descending order by quality score and break ties with additional metrics.

10 Dividend Growth Stocks - March 2023

Despite dealing with a pharmaceutical company, Bristol-Myers Squibb's performance during recessions was mixed and the stock also performed horrible in the last two decades. For fiscal 2022, the company also reported mediocre results.

Bristol-Myers Squibb: Growth Story And Valuation Is Convincing

Investors have assigned a higher multiple to LLY stock due to its robust pipeline and better profitability, as discussed below If we look at stock returns, Eli Lilly, with 15% returns in the last twelve months, has fared better than BMS, down 5%, and the broader S&P 500 index, down 11%.

Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer?

Amgen

Look no further if you want yield and distribution growth in a large-cap name with a blue-chip appeal. A simple screen using Marketbeat.com's dividend screener will turn up names like Comcast (NASDAQ: CMCSA), Bristol-Myers Squibb (NYSE: BMY), and Amgen (NYSE: AMGN), among others.

These Are The Top 3 Large Caps For Yield And Dividend Growth

LONDON--(BUSINESS WIRE)--CHARM Therapeutics announces collaboration with Bristol Myers Squibb to enable and accelerate small molecule drug discovery programs.

CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs

Novo Nordisk

Bristol Myers Squibb is counting on new approvals to fill the hole left by older medicines. Novo Nordisk is second to none in diabetes care, and it is expanding beyond this area.

2 Top Healthcare Stocks to Buy for the Long Haul

Verizon

Bristol Myers and Verizon both pay above-average dividend yields. These payouts are not only safe but could potentially grow as well.

Got $5,000? These 2 High-Yielding Dividend Stocks Are Near Their 52-Week Lows

Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments

CVS Health

Investors are often on the lookout for strong companies that may be undervalued and present lucrative long-term opportunities.

Should Investors Buy Bristol Myers or CVS Stock Near 52-week Lows?

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023

Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023

Start Time: 09:50 January 1, 0000 10:22 AM ET Bristol-Myers Squibb Company (NYSE:BMY ) Cowen 43rd Annual Healthcare Conference March 07, 2023, 09:50 AM ET Company Participants Samit Hirawat - EVP, Chief Medical Officer, and Drug Development Conference Call Participants Steve Scala - Cowen and Company Mike Nedelcovych - Cowen and Company Steve Scala Welcome to the Cowen conference. Representing the company is Samit Hirawat, who is Executive Vice President and Chief Medical Officer and the Global Head of Drug Development.

Bristol-Myers Squibb Company (BMY) Presents at Cowen 43rd Annual Healthcare Conference (Transcript)

Bristol Myers Squibb (BMY) gets full marketing authorization from the European Commission, for Reblozyl for anemia associated with non-transfusion-dependent beta thalassemia treatment drug in adult patients.

Bristol Myers (BMY) Gets EU Nod for Anemia Drug Reblozyl

SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, a leader in AI-powered disease detection and care coordination, today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY), a global biopharmaceutical company, to deploy an artificial intelligence (AI) algorithm and provider workflow software (VizTM HCM) intended to identify and triage patients who may require further evaluation for the detection of hypertrophic cardiomyopathy. Viz.ai has submitted a de novo request to the U.S.

Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM)

Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia

The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor

Bristol Myers Squibb stock (NYSE: BMY) has seen a fall of 3% in a month, compared with -4% returns for the broader S&P500 index.

Does Bristol Myers Squibb Stock Have More Room For Growth?

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Participate in Cowen's 43rd Annual Health Care Conference

Bristol Myers Squibb to Participate in Cowen's 43rd Annual Health Care Conference

American Electric Power Company

Colgate-Palmolive

Kroger

Union Pacific

The simple black dress is considered a foundational piece. It just doesn't go out of fashion.

News for Bristol-Myers Stock (BMY)